JIVZX
Price
$32.64
Change
-$0.23 (-0.70%)
Updated
Nov 14 closing price
RMFCX
Price
$58.73
Change
-$0.40 (-0.68%)
Updated
Nov 14 closing price
Ad is loading...

JIVZX vs RMFCX

Header iconJIVZX vs RMFCX Comparison
Open Charts JIVZX vs RMFCXBanner chart's image
JPMorgan U.S. Applied Data Sci Val R2
Price$32.64
Change-$0.23 (-0.70%)
VolumeN/A
CapitalizationN/A
American Funds American Mutual R3
Price$58.73
Change-$0.40 (-0.68%)
VolumeN/A
CapitalizationN/A
JIVZX vs RMFCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JIVZX vs. RMFCX commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JIVZX is a Buy and RMFCX is a Buy.

FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 106B vs. JIVZX (181M). RMFCX pays higher dividends than JIVZX: RMFCX (1.69) vs JIVZX (1.16). JIVZX was incepted earlier than RMFCX: JIVZX (16 years) vs RMFCX (22 years). RMFCX is a more actively managed with annual turnover of: 25.00 vs. JIVZX (17.00). JIVZX has a lower initial minimum investment than RMFCX: JIVZX (0) vs RMFCX (250). RMFCX (22.78) and JIVZX (22.58) have marching annual gain over last year. RMFCX return over 5 years is better than : 46.17 vs. JIVZX (8.13).
JIVZXRMFCXJIVZX / RMFCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years22 years-
Gain YTD20.85417.440120%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets181M106B0%
Annual Yield % from dividends1.161.6968%
Returns for 1 year22.5822.7899%
Returns for 3 years-12.5516.54-76%
Returns for 5 years8.1346.1718%
Returns for 10 years-4.7267.25-7%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NPWR13.100.26
+2.02%
NET Power
UA8.910.12
+1.37%
Under Armour
EG366.50-4.18
-1.13%
Everest Group Ltd
DLHC8.47-0.29
-3.31%
DLH Holdings Corp
NLSP3.34-0.12
-3.47%
Nls Pharmaceutics Ltd